Literature DB >> 15106298

The role of routine polio immunization in the post-certification era.

Roland W Sutter1, Victor M Cáceres, Pedro Mas Lago.   

Abstract

The role of routine vaccination against poliomyelitis for the post-certification era remains an important area for policy decision-making. Two critical decisions need to be taken: first, to continue or discontinue vaccination with the live attenuated oral poliovirus vaccine (OPV); and second, if OPV is to be discontinued, whether vaccination with inactivated poliovirus vaccine (IPV) is needed. Four potential vaccination scenarios can be constructed: stop all polio vaccination; continue with current vaccination policies (OPV, IPV, or sequential schedule); discontinue OPV, but continue IPV universally; or discontinue OPV, but continue IPV in selected countries. All possible scenarios require continued investments in a surveillance and response strategy, including a stockpile of polio vaccine. Continuing vaccination would limit the savings that could be applied to the control of other health priorities. This report reviews the key issues associated with each scenario, highlights the advantages and disadvantages of each scenario, and outlines the major challenges for policy decision-making.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15106298      PMCID: PMC2585885     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  11 in total

1.  Isolation of vaccine-derived polioviruses in the Slovak Republic.

Authors:  B Cernáková; Z Sobotová; I Rovný; S Bláhova; M Roivainen; T Hovi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

2.  The risks, costs, and benefits of possible future global policies for managing polioviruses.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens; Mark A Pallansch; Olen M Kew; Roland W Sutter; R Bruce Aylward; Margaret Watkins; Howard E Gary; James Alexander; Hamid Jafari; Stephen L Cochi
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

3.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

4.  Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.

Authors:  Lei Ma; Wei Cai; Mingbo Sun; Yina Cun; Jian Zhou; Jing Liu; Wenzhu Hu; Xinwen Zhang; Shaohui Song; Shude Jiang; Guoyang Liao
Journal:  Hum Vaccin Immunother       Date:  2016-08-15       Impact factor: 3.452

5.  Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Authors:  Janny Westdijk; Patrick Koedam; Mario Barro; Benjamin P Steil; Nicolas Collin; Thomas S Vedvick; Wilfried A M Bakker; Peter van der Ley; Gideon Kersten
Journal:  Vaccine       Date:  2013-01-09       Impact factor: 3.641

Review 6.  From emergence to eradication: the epidemiology of poliomyelitis deconstructed.

Authors:  Neal Nathanson; Olen M Kew
Journal:  Am J Epidemiol       Date:  2010-10-26       Impact factor: 4.897

Review 7.  Is EU/EEA population protected from polio?

Authors:  Dre Nijsten; P Carrillo-Santisteve; A Miglietta; J Ruitenberg; P L Lopalco
Journal:  Hum Vaccin Immunother       Date:  2015-04-21       Impact factor: 3.452

8.  Increasing Type 1 Poliovirus Capsid Stability by Thermal Selection.

Authors:  Oluwapelumi O Adeyemi; Clare Nicol; Nicola J Stonehouse; David J Rowlands
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

9.  An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia.

Authors:  Kathleen M O'Reilly; Christine Lamoureux; Natalie A Molodecky; Hil Lyons; Nicholas C Grassly; Graham Tallis
Journal:  BMC Infect Dis       Date:  2017-05-26       Impact factor: 3.090

10.  Dangerous pathogens in the laboratory: from smallpox to today's SARS setbacks and tomorrow's polio-free world.

Authors:  David L Heymann; R Bruce Aylward; Christopher Wolff
Journal:  Lancet       Date:  2004-05-15       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.